EX-99.1 2 v147677_ex99-1.htm
Exhibit 99.1

Company Contact:
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com


MANNKIND CORPORATION REPORTS FIRST QUARTER OF 2009 FINANCIAL RESULTS
 
 
- Conference Call to Begin Today at 4:00 PM EDT -
 
 
VALENCIA, Calif., May 4 /Business Wire/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the first quarter ended March 31, 2009.
 
For the first quarter of 2009, total operating expenses were $57.8 million, compared to $74.1 million for the first quarter of 2008. Research and development (R&D) expenses decreased by $15.6 million to $42.9 million for the first quarter of 2009 compared to the first quarter of 2008.  This decrease in R&D expenses as compared to the same period in the prior year was primarily due to decreased costs associated with the clinical development of AFRESA® as well as decreased manufacturing costs associated with raw material purchases.  General and administrative (G&A) expenses decreased by $0.7 million to $14.9 million for the first quarter of 2009 compared to the first quarter of 2008.
 
The net loss applicable to common stockholders for the first quarter of 2009 was $59.4 million, or $0.58 per share, based on 102.0 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $71.4 million, or $0.70 per share based on 101.4 million weighted average shares outstanding, for the first quarter of 2008.
 
Cash, cash equivalents and marketable securities were $30.2 million at March 31, 2009 compared to $46.5 million at December 31, 2008, and $269.1 million at March 31, 2008. Currently, the Company has $260.0 million of available borrowings under the loan agreement with an entity controlled by the Company’s principal stockholder.
 
"This past quarter was extremely busy for MannKind," said Alfred Mann, Chairman and Chief Executive Officer, "culminating in our submission to the FDA of a New Drug Application for AFRESA.  With this milestone accomplished, we are now turning our attention to commercial readiness activities."
 
Conference Call
 
MannKind management will host a conference call to discuss these results today at 4:00 PM EDT. To participate in the call, please dial (888) 677-5721 or (210) 839-8507. To listen to the call via the internet, please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (888) 566-0513 or (203) 369-3063.
 
 
 
 
 
Presenting from the Company will be:
 
·  Chairman and Chief Executive Officer Alfred Mann
·  President and Chief Operating Officer Hakan Edstrom
·  Corporate Vice President and Chief Financial Officer Matthew Pfeffer
·  Corporate Vice President and Chief Scientific Officer Peter Richardson
 
About MannKind Corporation
 
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA, an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1.  MannKind also has two cancer immunotherapeutic products in clinical development.  MannKind maintains a website at http://www.mannkindcorp.com to which the company regularly posts copies of its press releases as well as additional information.  Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
 
Forward-Looking Statements
 
This press release contains forward-looking statements, including statements related to MannKind’s commercial readiness activities. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the difficulties or delays in seeking or obtaining regulatory approval, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2008 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
 

(Tables to follow)

 
 
 
MannKind Corporation and Subsidiaries
(A Development Stage Company)
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share amounts)
 
   
 
 
Three months ended
March 31,
    
Cumulative
period from
February 14,
1991 (date of
inception) to
March 31,
  
   
2009
    
2008
    
2009
  
                   
Revenue
   $ —     $ 20     $ 2,988  
Operating expenses:
                        
Research and development
     42,889       58,445       1,040,371  
General and administrative
     14,917       15,640       260,759  
In-process research and development costs
     —       —       19,726  
Goodwill impairment
     —       —       151,428  
Total operating expenses
     57,806       74,085       1,472,284  
Loss from operations
     (57,806 )     (74,065 )     (1,469,296 )
Other income (expense)
     71       60       (1,872 )
Interest expense on note payable to related party
     (593 )     —       (2,116 )
Interest expense on senior convertible notes
     (1,115 )     (337 )     (7,072 )
Interest income
     31       2,921       36,892  
Loss before provision for income taxes
     (59,412 )     (71,421 )     (1,443,464 )
Income taxes
     —       —       (26 )
Net loss
     (59,412 )     (71,421 )     (1,443,490 )
Deemed dividend related to beneficial conversion feature of convertible preferred stock
     —       —       (22,260 )
Accretion on redeemable preferred stock
     —       —       (952 )
Net loss applicable to common stockholders
   $ (59,412 )   $ (71,421 )   $ (1,466,702 )
Net loss per share applicable to common stockholders — basic and diluted
   $ (0.58 )   $ (0.70 )        
Shares used to compute basic and diluted net loss per share applicable to common stockholders
     102,030       101,409          


 
 
 

MannKind Corporation and Subsidiaries
(A Development Stage Company)
Condensed Consolidated Balance Sheet
(Unaudited)
(in thousands)

   
March 31, 2009
    
December 31, 2008
  
             
Assets
            
Current assets:
            
Cash and cash equivalents
   $ 27,114     $ 27,648  
Marketable securities
     3,115       18,844  
State research and development credit exchange receivable — current
     —       1,500  
Prepaid expenses and other current assets
     4,907       5,983  
Total current assets
     35,136       53,975  
Property and equipment — net
     228,352       226,436  
State research and development credit exchange receivable — net of current portion
     1,675       1,500  
Other assets
     10,548       548  
Total
   $ 275,711     $ 282,459  
 
Liabilities and Stockholders’ Equity
                
                 
Current liabilities
   $ 40,159     $ 53,472  
Senior convertible notes
     112,378       112,253  
Note payable to related party
     90,000       30,000  
Other liabilities
     —       —  
Stockholders’ equity
     33,174       86,734  
Total
   $ 275,711     $ 282,459  
 
###